Predicting disease progression in high-grade glioma with neuropsychological parameters:
Butterbrod, Elke; Bruijn, J.; Braaksma, Meriam; Rutten, Geert-Jan; Tijssen, Cees; Hanse, Monique; Sitskoorn, Margriet; Gehring, Karin

Published in:
Journal of Neuro-Oncology

Document version:
Publisher's PDF, also known as Version of record

DOI:
10.1007/s11060-019-03249-1

Publication date:
2019

Citation for published version (APA):
Butterbrod, E., Bruijn, J., Braaksma, M., Rutten, G-J., Tijssen, C., Hanse, M., ... Gehring, K. (2019). Predicting disease progression in high-grade glioma with neuropsychological parameters: The value of personalized longitudinal assessment. Journal of Neuro-Oncology, 144(3), 511-518. https://doi.org/10.1007/s11060-019-03249-1

General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal

Take down policy
If you believe that this document breaches copyright, please contact us providing details, and we will remove access to the work immediately and investigate your claim.
Predicting disease progression in high-grade glioma with neuropsychological parameters: the value of personalized longitudinal assessment

Elke Butterbrod\textsuperscript{1} \& Jimme Bruijn\textsuperscript{1} \& Meriam M. Braaksma\textsuperscript{2} \& Geert-Jan M. Rutten\textsuperscript{3} \& Cees C. Tijssen\textsuperscript{2} \& Monique C. J. Hanse\textsuperscript{4} \& Margriet M. Sitskoorn\textsuperscript{1} \& Karin Gehring\textsuperscript{1,3}

Received: 22 May 2019 / Accepted: 19 July 2019
© The Author(s) 2019

Abstract

Purpose Progressive disease in patients with high-grade glioma may be reflected in cognitive decline. However, the cognitive functions most sensitive to progression may differ between patients. We investigated whether decline on a personalized selection of tests predicted progressive disease according to RANO criteria in high-grade glioma patients.

Methods Starting one day before surgery, patients underwent neuropsychological assessment every three months during standard treatment and clinical follow-up. We first made a personalized selection of three tests that showed the highest Reliable Change Index (RCI) values, i.e., most positive change, at the first post-surgical assessment for each patient. In subsequent follow up, a decline of RCI ≤ −1 on at least two of the three tests in the selection was considered cognitive decline. We performed a discrete Cox proportional hazards model including a time-dependent coefficient cognitive decline (vs. stability) and covariate age to predict progressive disease.

Results Twenty five patients were included. Cognitive decline on the personalized test selection preceded or had occurred by the time progression was established in 9/15 patients with RANO confirmed progressive disease (60%). Decline was absent in 8/10 patients (80%) with stable disease during participation. The independent hazard ratio for progression in case of cognitive decline was 5.05 (p < 0.01) compared to stable performance.

Conclusions Using only three patient-specific neuropsychological tests, we found a fivefold increased chance of disease progression in case of cognitive decline as compared to stable performance. Brief, patient-tailored cognitive assessment may be a noninvasive addition to disease monitoring without overburdening patients and clinical care.

Keywords Cognitive functioning \cdot High-grade glioma \cdot RANO \cdot Disease progression \cdot Neuropsychological assessment

Introduction

Identification of reliable prognostic indicators for disease progression and overall survival is a principal aim in care for patients with high-grade gliomas (HGG), for treatment planning and to inform patients. Age and performance status (PS) are generally considered the major prognostic factors from a clinical perspective [1–3]. These characteristics, however, may be interrelated with or confounded by other factors, such as therapeutic strategy or varying disease symptoms [1, 4], that are not always accounted for.

Interest in the prognostic value of cognitive functioning in the clinical management of glioma patients is growing [1, 5–9]. Cognitive functioning depends on neuronal synchrony across brain regions [10]. Invasive growth, reactive changes in peritumoral tissue and increased intracranial pressure may
all disrupt network functioning needed for cognitive performance [11].

Cognitive status before surgery or oncological treatment has been reported as a predictor of (progression-free) survival time [7] independent of age and Karnofsky PS (KPS) [9] and within RPA-RTOG classes [12]. Furthermore, Meyers [8] reported that performance decline over time on one of nine cognitive tests preceded radiological evidence of progressive disease (PD) in HGG in 85% of cases and by a median of 4 to 7 weeks. In a heterogeneous sample of patients with brain tumors, Armstrong and colleagues [5] showed that a decline of one standard deviation (SD) on the standardized mean of three to five tests per patient selected based on tumor location, was accompanied by a fivefold increase in chance of PD.

Cognitive deterioration over time might thus provide information about tumor activity during the course of the disease [5, 8, 13, 14]. A targeted test selection, e.g., tumor location-based as done by Armstrong [5] may increase efficiency of assessment. However, dysfunction of specific cognitive domains may not be reliably determined by location alone [15, 16] as tumors affect cerebral functioning outside their location [17].

In this study, we argue that disease-related cognitive dysfunction in HGGs, and individual differences therein, may also be detected by considering the manner in which a patient’s performance changes early after tumor resection. We hypothesize that the functions that show the largest recovery shortly after surgery are the ones that suffered the largest burden from tumor-related edema and mass effect, and that these same functions may deteriorate first amid recurrent disease activity. In a sample of newly diagnosed HGG, we constructed a personalized test selection for each patient, based on a subset of three neuropsychological tests that demonstrated most improvement within three months after resection. We subsequently investigated whether deterioration on this selection coincided with, and predicted PD.

Materials and methods

Patients

Patients undergoing resection at the Elisabeth-TweeSteden Hospital (ETH), Tilburg, the Netherlands, between August 2015 and September 2017 for histopathologically confirmed grade III AA or GBM were included. Patients received clinical follow up either at ETH or Catharina Hospital (CH) in Eindhoven, the Netherlands. Exclusion criteria were age < 18, presence of progressive neurological disease, psychiatric or acute neurological disorder within the past 2 years, previous intracranial surgery, reduced testability (e.g., lack of proficiency in Dutch, estimated IQ < 85). All participants provided written informed consent.

Study procedure and design

At the neurosurgery department of ETH, patients with brain tumors undergo neuropsychological assessment (NPA) as part of clinical care 1 day before (T0) and 3 months after (T3) neurosurgical treatment. Around T3, patients were asked to participate in this prospective longitudinal study by a neuro-oncology nurse practitioner, and underwent three monthly NPA and MRI, for up to 24 months after surgery (T24; 9 NPA’s in total) or until confirmed progressive disease (PD) at their clinical follow-up site. NPA and MRI were performed on the same day, but NPA was always done before the patient was informed of the results of the MRI. Approval for the study was given by Medical Ethics Committee Brabant (File No. NL41351.008.12).

Measures

Sociodemographic and clinical measures

Sociodemographic information was gathered through semi-structured interview at T0. Clinical information (tumor characteristics, extent of resection, KPS, medication, adjuvant treatment) was retrieved from electronic charts. Pre-surgical tumor volumes were determined through semi-automatic segmentation using BrainLab Elements [18] software on T1-post contrast enhanced series.

Neuropsychological assessment

The Dutch translation of the CNS Vital Signs (CNS VS) computerized test battery consists of seven tasks based on conventional paper-and-pencil tests [19]. Completion using the local software application on a notebook computer took 30–40 min. Two additional paper-and-pencil tasks were administered: Digit Span task [20], and a Letter Fluency task [21]. An overview of task content and score computation is provided in the supplementary Table. Trained test administrators conducted assessments.

MRI-cerebrum and time until PD

Evaluations of the three monthly MRI scans were conducted by a trained neurologist (MB) under supervision of a senior neurologist (CT), both unaware of patients’ cognitive status. The baseline for comparison follow up MRI scans (at T3, T6, etc.) was the first post-operative scan (≤ 48 h after surgery). We adopted the response assessment criteria for HGG by the RANO Working Group [22] for disease status evaluation: (1) ≥ 25% increase of the product of the
maximum diameters of contrast-enhancing lesions (2) significant increase of lesions in T2-weighted/ FLAIR series (3) presence of new contrast-enhancing lesions outside radiation field (4) significant clinical deterioration not attributable to medication or comorbid conditions, or (5) clear progression of a non-measurable lesion.

**Cognitive change as a personalized predictor**

**Reliable change**

Regression-based Reliable Change Indices (RCI), aimed at determining whether change between assessments in individual patients reflected relevant change, controlling for confounding factors related to repeated testing (e.g. flawed test–retest reliability, practice effects) [23, 24], were computed for each of the 10 test scores. A positive RCI value indicates improvement, a negative RCI value indicates decline. RCIs were based on repeated testing data of healthy Dutch individuals from Rijnen [24] (CNS VS), Schmand [21] (Letter Fluency), and an ongoing study in the ETH (Digit Span test); CAR study A, ClinicalTrials.gov reference nr. NCT02953756.

**Personalized selection and criterion for cognitive decline (CD)**

For each patient, the three tests with the highest RCIs between T0 and T3 were selected. We opted to select three tests in accordance with previous similar studies [5, 8], and with the goal of a small selection of tests for potential future clinical purposes. All follow-up RCIs were calculated using T3 NPA as baseline (T6–T3, T9–T3, etc.). CD was defined as RCI ≤ − 1.00, reflecting a standardized difference score of − 1, on at least two of the three selected tests at any follow up interval.

**Statistical analyses**

Using the Survival package in Rstudio, a discrete Cox proportional hazards model with two covariates was performed (α = 0.05): a dichotomous time-dependent covariate (CD vs. stable performance) and age at time of surgery. Cases who dropped out before PD, completed follow up (T24) progression-free, or showed stable disease at the end of the study (August 2018), were censored. Median time to PD and to CD were computed. Z-scores, corrected for age, sex and educational level based on a healthy control sample [25] were computed to investigate whether patients had cognitive impairment before surgery (Z ≤ − 1.5). Group-level characteristics of patients with PD, without PD, with CD, and without CD were computed (no statistical comparisons due to sample sizes).

**Results**

**Patients**

Thirty-five of 70 (50%) patients eligible for participation were included in the study. Unwillingness, anticipated intensity of repeated NPA, and follow-up care in a non-participating center were reasons for declining participation. Ten out of 35 patients were excluded from analyses, because of invalid or incomplete T0 NPA (n = 6), or absent T6 data (consent withdrawal; n = 3, referral to non-participating treatment center; n = 1). Analyses showed no differences in age, tumor volume, extent of resection or pre-operative KPS between excluded patients and the final sample.

The final sample comprised four anaplastic astrocytoma (AA) and 21 glioblastoma (GBM). Mean age at time of surgery was 53 ± 14 years. See Table 1 for an overview of sample characteristics and Table 2 for the personalized test selection per patient. All patients started adjuvant

| Table 1 Sample characteristics | \( N = 25 \) |
|--------------------------------|-----------|
| **Characteristic** |    |
| Male \( n \) (%) | 17 (68%) |
| Age at time of surgery (M±SD, range) | 53 ± 14, 19–76 |
| Educational level\( ^a \) |    |
| Low \( n \) (%) | 3 (12%) |
| Middle \( n \) (%) | 12 (48%) |
| High \( n \) (%) | 10 (40%) |
| Diagnosis |    |
| Glioblastoma | 21 (84%) |
| Anaplastic astrocytoma | 4 (16%) |
| Tumor volume (cm\(^3\), median (range) | 37 (4.4–162) |
| KPS before surgery, mode (range) | 90, 80–100 |
| Tumor lateralization \( n \) (%) |    |
| Right | 15 (60%) |
| Left | 10 (40%) |
| Tumor location \( n \) (%) |    |
| Frontal | 6 (24%) |
| Fronto–parietal | 1 (4%) |
| Parietal | 3 (12%) |
| Parietal–temporal | 2 (8%) |
| Parietal–occipital | 4 (16%) |
| Temporal | 3 (12%) |
| Occipital | 6 (24%) |
| Corticosteroids before surgery | 17 (68%) |
| Anti-epileptics before surgery | 8 (32%) |
| Macroscopic extent of resection |    |
| Gross total resection (>90%) | 17 (68%) |
| Gross subtotal resection (<90%) | 8 (31%) |

\(^a\)Classified according to Verhage education coding system [31]
chemoradiation according to protocol [26]. Twenty-one patients completed treatment as planned during study participation. Temozolomide monotherapy was discontinued in four patients, either on patient’s request \((n = 1, \text{around T6})\), because of PD during \((n = 2, \text{around T6})\) or due to treatment-related toxicity \((n = 1, \text{between T6 and T9})\).

In 23 out of 25 patients, all three selected tests with the highest RCI from T0 to T3 were positive scores \((> 0)\), indicating improvement after surgery. In two patients, the selection also contained tests with negative values (highest RCI’s were 0.62, 0.23, and −0.25 in one patient, 1.76, −0.18, and −0.20 in another patient).

Fifteen out of 25 patients \((60\% \text{ of the sample})\) showed PD according to RANO during follow up (see Table 3 for evaluations of PD). Eleven out of 25 showed CD during follow up. Within the “PD group”, the median time-point to PD was T9, while within the “CD group”, the median time-point to CD was T6.

CD preceded \((n = 4)\) or was present at time of \((n = 5)\) PD in nine out of 15 patients with PD. See Fig. 1 for a visualization of individual follow-up periods and the timing of CD relative to PD. Five of the six patients who showed stable cognitive performance according to our criterion, despite PD, showed RCI ≤ −1 on one of their selected tests at time of PD, while showing no RCI ≤ −1 on their unselected tests. In 10 of 25 patients \((40\%\) ), PD did not occur during study participation. Eight out ten \((80\%\) ) were stable performers throughout follow up (median follow up time-point T12, range T6–T24). Two patients showing CD despite stable disease, did so at T6 and T9 respectively.

Table 3 shows descriptive characteristics of the four groups (no statistical comparisons). The group demonstrating both CD and PD was the only group in which KPS below 90 was observed at time of final NPA. AED use was high among these patients compared to the other groups, but the majority \((four out of six)\) used medication because

| Diagnosis | Age | Location | Hemisphere | Selected tests | Impairment on selected tests at T0 | PD during follow up |
|-----------|-----|----------|------------|----------------|-----------------------------------|---------------------|
| GBM       | 18–20 | Frontal | Left       | SAT, LF, SDC   | 3/3                               | No\(^c\)            |
| GBM       | 60–70 | Parieto–occipital | Right     | SAT, VEM, SDC  | 2/3                               | Yes                 |
| AA        | 30–40 | Frontal | Left       | DSFW, LF, SAT  | 1/3                               | No\(^c\)            |
| GBM       | 60–70 | Occipital | Left       | VIM, DSB, DSC  | 0/3                               | Yes                 |
| GBM       | 50–60 | Occipital | Right      | SDC, CPT, FTT  | 2/3                               | Yes                 |
| GBM       | 50–60 | Fronto–parietal | Right     | SAT, VIM, VEM  | 1/3                               | Yes                 |
| GBM       | 40–50 | Frontal | Right      | SAT, CPT, FTT  | 2/3                               | Yes                 |
| GBM       | 60–70 | Parietal | Right      | CPT, SAT, VEM  | 3/3                               | Yes                 |
| GBM       | 60–70 | Occipital | Right      | VIM, SAT, VEM  | 3/3                               | Yes                 |
| GBM       | 40–50 | Frontal | Left       | FTT, CPT, SAT  | 0/3                               | Yes                 |
| GBM       | 50–60 | Parieto–occipital | Left     | SAT, CPT, SDC  | 1/3                               | No\(^b\)            |
| GBM       | 50–60 | Parietal | Left       | SAT, VIM, FTT  | 3/3                               | Yes                 |
| GBM       | 50–60 | Parieto–occipital | Right    | FTT, CPT, SDC  | 3/3                               | No\(^b\)            |
| AA        | 30–40 | Frontal | Right      | VIM, VEM, LF   | 0/3                               | No\(^c\)            |
| GBM       | 60–70 | Temporo–parietal | Left      | FTT, SAT, Stroop | 0/3                             | Yes                 |
| GBM       | 70–80 | Parietal | Right      | FTT, SAT, Stroop | 2/3                             | Yes                 |
| GBM       | 50–60 | Frontal | Right      | FTT, VIM, DSC  | 0/3                               | Yes                 |
| GBM       | 50–60 | Occipital | Right      | VEM, VIM, LF   | 2/3                               | Yes                 |
| GBM       | 50–60 | Temporo–parietal | Left      | FTT, VEM, Stroop | 0/3                             | Yes                 |
| GBM       | 30–40 | Occipital | Right      | FTT, DSC, SDC  | 2/3                               | No\(^b\)            |
| GBM       | 70–80 | Temporal | Right      | Stroop, SAT, VIM | 0/3                             | Yes                 |
| GBM       | 50–60 | Occipital | Right      | VIM, Stroop, FTT | 1/3                             | No\(^a\)            |
| GBM       | 50–60 | Mesiotemporal | Left      | FTT, LF, SDC   | 3/3                               | No\(^a\)            |
| AA        | 50–60 | Temporal | Right      | SAT, SDC, DSC  | 3/3                               | No\(^a\)            |
| AA        | 20–30 | Parieto–occipital | Left     | FTT, VEM, DSB  | 2/3                               | No\(^a\)            |

\(^a\) Active participation at end of study
\(^b\) Dropout before PD
\(^c\) Completion of T24 without PD
of a pre-surgical insult. The other two started AED therapy due to a seizure during follow up (both in the interval prior to PD). The group with stable disease and stable cognitive performance appeared relatively young and to comprise fewer males compared to the other groups.

The Cox proportional hazards model showed a hazard ratio (HR) for PD of 5.05; 95% CI 1.50–17.02, p < 0.01 (model $\chi^2[1] = 13.6$, $p < 0.01$, c-index = 0.80), suggesting a 405% increase in chance of RANO-confirmed PD if patients met the criterion of CD compared to stable cognitive performance, independent of age. Age itself was not a significant predictor (HR = 1.04, $p > 0.1$) of PD.

### Discussion

This study investigated whether post-surgical cognitive decline (CD) on a personalized selection of three neuropsychological tests concurred with and predicted progressive disease (PD) according to RANO [22] in 25 patients with GBM or AA.

Decline in cognitive performance—deterioration of at least one RCI point on at least two of the three selected tests—concurred with, or manifested one or two interval(s) before, RANO-confirmed PD in nine out of 15 (60%) of patients.
recurrences. Of the six patients with PD who did not meet our criterion for CD, five showed $\text{RCI} \leq -1$ on one of their selected tests, but no such decline on their unselected tests. Further consistent with our hypothesis and previous reporting [27], eight out of 10 patients with stable disease remained cognitively stable throughout participation. The predictive model showed a 405% increase in chance for PD (HR = 5.05) in case of CD, independent of age.

Our findings support existing reports of (change in) cognitive functioning as a clinical marker of disease activity in patients with brain tumors [5, 8, 13, 28]. Gradual, widespread impairment of network functioning over time may underlie the sensitivity of cognitive performance to disease progression. Using a uniform test selection in patients with recurrent HGG, Meyers and colleagues [8] reported a higher proportion of patients showing CD (48/56 patients, CD was defined as $\text{RCI} \leq -1.645$ on one of nine tests) before, or at time of, PD compared to our study. It could be that CD emerges sooner in patients with progression of already recurred HGG. Still, the described criterion for decline was based on a more stringent cutoff, but for only one test, and time between CD and actual PD seemed to vary considerably among patients. Their reported prediction model (requiring decline on one of three uniform tests) yielded a HR for PD of 2.0 in case of CD.

The hazard ratio of CD (one standard deviation in mean performance) on a tumor location-based selection of three to five tests found by Armstrong [5] in a sample of 34 patients with glial and non-glial tumors, of which 11 demonstrated recurrence, was comparable to the one we found. As stated, reliable inferences about cognitive (dys-)function may not be based on tumor location alone [15]. In our sample of mainly GBMs, we did not observe a one-to-one relationship between tumor location and the personalized selection of tests, e.g., Letter Fluency and Shifting Attention tests were selected in patients with occipital tumors. The relative value of selection approaches (uniform, location-specific, personalized) within the context of prediction of PD may be compared in one larger sample in the future.

The absence of a gold standard concerning the cut off for CD, irrespective of the selection approach, in settings where cognition is used as a predictive instead of an outcome measure also warrants further investigation. The used $\text{RCI}$ is a suitable measure for change as it conveys a cautious estimation of decline. Selecting three tests per patient is in accordance with previous approaches [5, 8] and preserves briefness required for repeated NPA in the HGG population. We must note that the widely adopted RANO criteria for HGG are based on current evidence [22] and will likely evolve in the future.

Cognitive performance can fluctuate over time due to factors (un-)related to disease activity, such as temporary corticosteroid use [29] or depressive symptoms [30]. It has however been suggested that the main cause of cognitive decline over time is the tumor itself [13]. Cognitive stability in eight out of 10 progression-free patients in this study also suggests that such factors did not disturb cognitive performance strongly ($\text{RCI}$’s remained $>-1$) or in a personalized pattern. The group with both CD and PD did seem to comprise a relatively large proportion of

![Fig. 1 Follow-up duration per patient and time of CD (filled circle) and PD. Lines stop at time of RANO PD (bold line) or end of participation (dotted line; censoring). Timing of CD differed between patients (one patient two intervals before PD, two patients one interval before PD, five patients at time of PD)](image-url)
patients using AED’s, although in the majority of cases due to a pre-surgical insult. It was also the only group that comprised patients with KPS < 90 at time of final NPA/ PD. Clinical status may have interplayed with cognitive functioning around the time of PD. We were unable to adopt post-surgical decline in KPS or a combined cognition-KPS classification in the statistical model due to sample size, but analysis of hazard rates associated with CD irrespective of (K)PS decline could be a next step in future research.

Sample characteristics should be taken into account in interpreting our results. We note that our sample primarily comprised patients with GBM, and the majority of AA patients did not show PD. Moreover, 50% of patients who were invited to participate in this study declined participation, e.g., due to anticipated intensity of repeated NPA. Patients in good clinical condition at time of inclusion might be overrepresented. Furthermore, only 12% of the included patients had low educational level. Different cognitive courses might exist between groups who differ on these variables.

Results from the personalized prediction model warrant further investigation to establish relevance in clinical practice. Personalized NPA may serve as a noninvasive method to complement decision making processes, such as timing of second-line therapy in case of unclear or seemingly limited tumor growth. Conducting targeted NPA between MRI scans may also allow for early detection of recurrent disease activity, e.g., in patients whose radiological evaluation is conducted over longer intervals due to other relatively favorable prognostic features.

Conclusion

In conclusion, our prediction model based on a personalized selection of three neuropsychological tests showed CD before or at time of PD in the majority of patients with HGG. Eighty percent of progression-free survivors showed stable cognitive performance. Patients demonstrating CD showed five times higher chance of PD compared to stable performers. Personalized, longitudinal NPA may provide a targeted and sensitive addition to monitoring of both cognitive and disease status without overburdening patients or care trajectories.

Funding This study is funded by CZ group, a Dutch non-profit health insurer’s foundation (Grant No. 201500028).

Compliance with ethical standards

Conflict of interest The authors declare that they have no conflict of interest.

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

References

1. Johnson DR, Wefel JS (2013) Relationship between cognitive function and prognosis in glioblastoma. CNS Oncol 2:195–201
2. Lamborn KR, Chang SM, Prados MD (2004) Prognostic factors for survival of patients with glioblastoma: recursive partitioning analysis. Neuro Oncol 6:227–235
3. Weller M, Felsberg J, Hartmann C, Berger H, Steinbach JP, Schramm J et al (2009) Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network. J Clin Oncol 27:5743–5750
4. Gately L, Collins A, Murphy M, Dowling A (2016) Age alone is not a predictor for survival in glioblastoma. J Neuro-Oncol 129:479–485
5. Armstrong CL, Goldstein B, Shera D, Ledakis GE, Tallent EM (2003) The predictive value of longitudinal neuropsychological assessment in the early detection of brain tumor recurrence. Cancer 97:649–656
6. Klein M, Postma T, Taphoorn M, Aaronson N, Vandertop W, Muller M et al (2003) The prognostic value of cognitive functioning in the survival of patients with high-grade glioma. Neurology 61:1796–1798
7. Lee S-T, Park C-K, Kim JW, Park M-J, Lee H, Lim J-A et al (2015) Early cognitive function tests predict early progression in glioblastoma. Neurooncol Pract 2:137–143
8. Meyers CA, Hess KR (2003) Multifaceted end points in brain tumor clinical trials: Cognitive deterioration precedes MRI progression. Neuro-oncology 5:89–95
9. Meyers CA, Hess KR, Yung WA, Levin VA (2000) Cognitive function as a predictor of survival in patients with recurrent malignant glioma. J Clin Oncol 18:646–650
10. Ulhaas PJ, Singer W (2006) Neural synchrony in brain disorders: relevance for cognitive dysfunctions and pathophysiology. Neuron 52:155–168
11. Habets EJ, Kloet A, Walchenbach R, Vecht CJ, Klein M, Taphoorn MJ (2014) Tumour and surgery effects on cognitive functioning in high-grade glioma patients. Acta Neurochir 156:1451–1459
12. Johnson DR, Sawyer AM, Meyers CA, O’neill BP, Wefel JS (2012) Early measures of cognitive function predict survival in patients with newly diagnosed glioblastoma. Neuro-oncology 14:808–816
13. Brown PD, Jensen AW, Felten SJ, Ballman KV, Schafer PL, Jackle KA et al (2006) Detrimental effects of tumor progression on cognitive function of patients with high-grade glioma. J Clin Oncol 24:5427–5433
14. Bosma I, Vos MJ, Heimans JJ, Taphoorn MJ, Aaronson NK, Postma TJ et al (2007) The course of neurocognitive functioning in high-grade glioma patients. Neuro-oncology 9:53–62
15. Anderson SW, Damasio H, Tranel D (1990) Neuropsychological impairments associated with lesions caused by tumor or stroke. Archives Neurol-Chicago 47:397–405
16. Carrera E, Tononi G (2014) Diaschisis: past, present, future. Brain 137:2408–2422
17. Heimans JJ, Reijneveld JC (2012) Factors affecting the cerebral network in brain tumor patients. J Neuro-Oncol 108:231–237
18. Brainlab AG (2018) Brainlab elements. BrainlabAG, Munich
19. Gualtieri CT, Johnson LG (2006) Reliability and validity of a computerized neurocognitive test battery, CNS Vital Signs. Arch Clin Neuropsych 21:623–643
20. Wechsler D (1997) WAIS-III administration and scoring manual. The Psychological Corporation, San Antonio
21. Schmand B, Groenink S, van den Dungen M (2008) Letter fluency: psychometric properties and Dutch normative data. Tijdschr Gerontol Geriat 39:64
22. Wen PY, Macdonald DR, Reardon DA, Cloughesy TF, Sorensen AG, Galanis E et al (2010) Updated response assessment criteria for high-grade gliomas: Response assessment in neuro-oncology working group. J Clin Oncol 28:1963–1972
23. Maassen GH, Bossema E, Brand N (2009) Reliable change and practice effects: outcomes of various indices compared. J Clin Exp Neuropsych 31:339–352
24. Rijnen SJM, van der Linden SD, Emons WHM, Sitskoorn MM, Gehring K (2018) Test-retest reliability and practice effects of a computerized neuropsychological battery: a solution-oriented approach. Psychol Assess 30:1652–1662
25. Rijnen SJ, Meskal I, Emons WH, Campman CA, van der Linden SD, Gehring K et al (2017) Evaluation of normative data of a widely used computerized neuropsychological battery: applicability and effects of sociodemographic variables in a Dutch sample. Assessment. https://doi.org/10.1177/1073191117727346
26. Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC et al (2009) Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 10:459–466
27. Hilverda K, Bosma I, Heimans JJ, Postma TJ, Peter Vandertop W, Slotman BJ et al (2010) Cognitive functioning in glioblastoma patients during radiotherapy and temozolomide treatment: initial findings. J Neuro-Oncol 97:89–94
28. Torres IJ, Mundt AJ, Sweeney PJ, Llanes-Macy S, Dunaway L, Castillo M et al (2003) A longitudinal neuropsychological study of partial brain radiation in adults with brain tumors. Neurology 60:1113–1118
29. Ismail MF, Lavelle C, Cassidy EM (2017) Steroid-induced mental disorders in cancer patients: a systematic review. Future Oncol 13:2719–2731
30. Rock PL, Roiser JP, Riedel WJ, Blackwell AD (2013) Cognitive impairment in depression: a systematic review and meta-analysis. Psychol Med 44:2029–2040
31. Verhage F (1983) Educational classification system for research purposes: revised version]. Academic Hospital Groningen, State University Groningen, Internal publication Groningen, the Netherlands

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.